[go: up one dir, main page]

US20100203127A1 - Large dose ribavirin formulations - Google Patents

Large dose ribavirin formulations Download PDF

Info

Publication number
US20100203127A1
US20100203127A1 US12/761,869 US76186910A US2010203127A1 US 20100203127 A1 US20100203127 A1 US 20100203127A1 US 76186910 A US76186910 A US 76186910A US 2010203127 A1 US2010203127 A1 US 2010203127A1
Authority
US
United States
Prior art keywords
ribavirin
tablet
dosage form
auc
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/761,869
Inventor
Donald Joseph KERRISH
Ravindra Dhanantwari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Three Rivers Pharmaceuticals LLC
Original Assignee
Three Rivers Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36181049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100203127(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Three Rivers Pharmaceuticals LLC filed Critical Three Rivers Pharmaceuticals LLC
Priority to US12/761,869 priority Critical patent/US20100203127A1/en
Assigned to THREE RIVERS PHARMACEUTICALS, LLC reassignment THREE RIVERS PHARMACEUTICALS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DHANANTWARI, RAVINDRA, KERRISH, DONALD JOSEPH
Assigned to THREE RIVERS PHARMACEUTICALS, LLC reassignment THREE RIVERS PHARMACEUTICALS, LLC CHANGE OF ADDRESS Assignors: THREE RIVERS PHARMACEUTICALS, LLC
Assigned to SUNTRUST BANK, AS ADMINISTRATIVE AGENT reassignment SUNTRUST BANK, AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: THREE RIVERS PHARAMCEUTICALS, LLC, THREE RIVERS PHARMACEUTICALS, LLC
Publication of US20100203127A1 publication Critical patent/US20100203127A1/en
Assigned to CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT reassignment CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: THREE RIVERS PHARMACEUTICALS, LLC
Assigned to THREE RIVERS PHARMACEUTICALS, LLC reassignment THREE RIVERS PHARMACEUTICALS, LLC RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: SUNTRUST BANK, AS ADMINISTRATIVE AGENT
Assigned to CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT reassignment CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: KADMON PHARMACEUTICALS, LLC
Priority to US13/441,560 priority patent/US20120207828A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the invention is generally directed to large dosage formulations of ribavirin.
  • Ribavirin (1- ⁇ -D-ribofuranosyl-1H-1,2,4-triazole-3-carbamide) is a broad-spectrum antiviral nucleoside analog. It is available as a capsule and tablet in both the brand and generic form in 200 mg strength. The Food and Drug Administration has approved ribavirin in combination with interferon alfa-2a or interferon alfa-2b for the treatment of hepatitis-C. Over 170 million people worldwide are chronically infected with the hepatitis-C virus (HCV). Ribavirin is available as a 200 mg tablet by Roche Laboratories under the brand COPEGUSTM and as a 200 mg capsule by Schering-Plough under the brand REBETOLTM.
  • the most common doses prescribed for patients are 800 mg, 1000 mg, and 1200 mg per day in divided doses for both the capsule and tablet dosage forms. These dosing regimens have the patient taking up to 6 capsules or tablets per day. Ribavirin is not often given by itself; it is generally a component of a multi-drug regimen (“drug cocktail”). Therefore patients taking ribavirin have to take a large number of drugs, not in the least of which is 4 to 6 capsules or tablets of ribavirin. Not surprisingly, lack of patient compliance is a significant issue.
  • HCV has about a 50 percent cure rate depending upon a patient's genotype. Everything must be done to ensure patient compliance to the therapy that lasts 6 to 12 months. If dosing is more convenient for the patient, then it follows that the patient will more likely comply with the dosing regimen for the duration of therapy, which has been proven to improve patient outcomes.
  • ribavirin From a convenience standpoint, one logical approach to the formulator would be to formulate a modified or sustained release form of ribavirin, which would result in fewer capsules or tablets taken daily. However, in the case of ribavirin, such an approach would not be successful.
  • the pharmacokinetics of ribavirin are controlled by the rate of elimination, not absorption. Therefore, modifying the rate of release or absorption of ribavirin would not likely affect the efficacy of ribavirin. In other words, sustained release formulations of ribavirin are likely not a solution in this instance.
  • the optimal dosage regimen is two times a day.
  • the inventors then strove to formulate dosage forms with a twice-a-day dosing regimen which would increase patient compliance while maintaining bioactivity similar to lower (e.g., 200 mg) dose formulations.
  • One aspect of the present invention is directed to an oral dosage form of ribavirin, preferably a capsule, tablet or caplet, in 400 mg to 600 mg dosage strengths.
  • Another aspect of the present invention is directed to dosage forms of ribavirin that increase patient compliance.
  • Another aspect of the invention is directed to dosage forms of ribavirin that satisfy a long-felt need in the market for ribavirin dosage forms.
  • Another aspect of the invention is directed to dosage forms of ribavirin comprising high amounts of ribavirin, relative to commercially available formulations, which have similar bioactivities to the commercially available formulations.
  • a further aspect of the invention is directed to a dosage form comprising 400 mg of ribavirin.
  • a further aspect of the invention is directed to a dosage form comprising 600 mg of ribavirin.
  • Another aspect of the invention is directed to dosage forms of ribavirin in unit dose packaging, such as blister packaging.
  • FIG. 1 shows mean in vivo ribavirin plasma levels of three formulations in a bioavailability study of 36 subjects.
  • COPEGUSTM 3 ⁇ 200 mg means that the brand name ribavirin product was given in a dosage of three 200 mg tablets.
  • RIBASPHERETM 3 ⁇ 200 mg means that the generic ribavirin product was given in a dosage of three 200 mg tablets.
  • RIBASPHERETM 1 ⁇ 600 mg means that a ribavirin product according to the invention was given at a dosage of one 600 mg tablet.
  • the term “dosage form” includes capsules and tablets, and the term “tablet” includes both tablets and caplets.
  • the dosage form of the invention is preferably a tablet, and more preferably a caplet.
  • the present application describes the development of dosage forms of ribavirin in 400 mg to 600 mg dosage strengths.
  • subjects were dosed with 600 mg tablets.
  • a corresponding number of COPEGUSTM and generic 200 mg tablets were used as a comparison.
  • FIG. 1 shows that the in vivo dissolution profile of a 600 mg tablet according to the present invention is similar to the dissolution profile of three 200 mg COPEGUSTM tablets.
  • the higher strength tablets according to the present invention are bioequivalent to the brand name product.
  • the preferred caplet shape makes it easier for the patient to swallow and the tablets are acceptable as not being too large in size.
  • the dosage forms of the present invention can be made of the same general ingredients (e.g., binders, fillers, disintegrants, lubricants and the like) and in the same manner as commercially available ribavirin tablets.
  • a tablet comprises one or more of the following inactive ingredients: microcrystalline cellulose; lactose; crosscarmellose sodium; Povidone; and magnesium stearate.
  • the tablet is coated and the coating preferably comprises: Opandry II Blue (which in turn comprises polyvinyl alcohol-part hydrolyzed, titanium dioxide, macrogel/PEG 3350, talc, and FD&C blue #2/indigo carmine aluminum lake); and carnauba wax.
  • a 400 mg tablet according to the present invention has hardness of from about 10.27 kp to about 12.88 kp, preferably 11.18 kp.
  • Another embodiment of a 400 mg tablet according to the present invention has a tablet weight of from about 0.5470 g to about 0.5535 g, preferably 0.5494 g.
  • Another embodiment of a 400 mg tablet according to the present invention has a tablet thickness of from about 4.86 mm to about 4.91 mm, preferably 4.89 mm.
  • Another embodiment of a 400 mg tablet according to the present invention has a tablet friability of from about 0.23% to about 0.26%, preferably 0.25%.
  • Another embodiment of a 400 mg tablet according to the present invention has a compression force of from about 13.5 kN to about 16.6 kN, preferably 14.9 kN.
  • a 600 mg tablet according to the present invention has hardness of from about 10.64 kp to about 12.58 kp, preferably 11.60 kp.
  • Another embodiment of a 600 mg tablet according to the present invention has a tablet weight of from about 0.8174 g to about 0.8357 g, preferably 0.8272 g.
  • Another embodiment of a 600 mg tablet according to the present invention has a tablet thickness of from about 6.38 mm to about 6.41 mm, preferably 6.39 mm.
  • Another embodiment of a 600 mg tablet according to the present invention has a tablet friability of from about 0.23% to about 0.33%, preferably 0.29%.
  • Another embodiment of a 600 mg tablet according to the present invention has a compression force of from about 12.2 kN to about 14.2 kN, preferably 13.1 kN.
  • Compression and film coating of the tablets according to the present invention may be accomplished by standard industry means.
  • tablets may be compressed using a 16-station Manesty Beta press using capsule shaped tooling.
  • the tablets may be film coated using a 24-inch Accela Cota pan equipped with 2 spray guns with a target air flow of about 300 cfm and an exhaust temperature of between about 50° C. to 55° C.
  • the pan speed and the target spray rate can be adjusted to suit the particular tablet being coated.
  • Opandry II Blue coating is used. Any suitable coating can be used in accordance with the present invention.
  • the tablets according to the present invention may be of any color, preferably blue, more preferably light-blue, medium blue, or dark blue.
  • the tablets can also be of any shape, preferably flat and oval-shaped.
  • the tablets may be dispensed in any form including blister packs and HDPE bottles, which may or may not include child-resistant closures with induction seals. Any number of tablets may be included in a unit dose package, such as a blister pack, including 2, 4, 6, 8, 10, 12, 16, 20, 24, 48 or 56.
  • Ribavirin plasma levels under fasting conditions produced after administration of (a) three Ribasphere® 200 mg tablets and (b) one Ribasphere® 600 mg tablet were compared with those produced after administration of three Copegus® 200 mg tablets.
  • the 200 mg and 600 mg Ribasphere® tablets are manufactured by Three Rivers Pharmaceuticals, LLC; ribavirin tablets.
  • the Copegus® 200 mg tablets were manufactured by Roche®.
  • the study was administered and coordinated by Bioanalytical Systems, Inc. (BASi), Clinical Research Unit (CRU), Baltimore, Md. The clinical portion of the study was conducted by Gateway Medical Research, Inc. The laboratory analysis of plasma samples and statistical analysis of the concentration-time data was conducted at BASi CRU. Forty-one healthy female subjects were enrolled in this three-treatment crossover study. Blood samples from all subjects who completed the study were analyzed. The subjects received a single oral dose of ribavirin 600 mg on three occasions separated by a washout period of three weeks. Blood samples were obtained at 15 time points from predose (0-hour) until 72 hours post-dose. The plasma samples were analyzed by a specific validated LC/MS/MS method to determine ribavirin concentrations.
  • the ribavirin concentrations were used to calculate the area under the concentration-time curve to the last non-zero time point (AUC 0-T ), elimination rate constant (K el ), half-life (T 1/2 ) and AUC 0-Infinity (AUC 0-Inf ). The actual times of sample collections were used in the calculations. The maximum drug concentration (C max ) and the time to maximum drug concentration (T max ) were also reported. The arithmetic mean and standard deviation were calculated for each parameter and for the ribavirin concentrations at each time point. The geometric means were calculated for AUC 0-T , AUC 0-Inf and C max . All parameters were analyzed by an analysis of variance (ANOVA) using the general linear model (GLM).
  • ANOVA analysis of variance
  • the ANOVA included effects for sequence of drug treatment, subject nested within sequence, period and drug treatment in the statistical model.
  • the F-test was employed to determine the statistical significance of each effect in the model.
  • the power of the study to detect a 20% difference in parameter means as statistically significant under a 2-tailed test at the 5% level of the t-distribution was calculated for each pharmacokinetic metric.
  • test and reference means and geometric means
  • ratios of means, test/reference were reported using the least squares means from the ANOVA.
  • An assessment of bioequivalence was conducted for the test versus reference product comparison of AUC and C max after log transformation using 90% confidence intervals for the differences in treatment means. These were transformed into 90% confidence intervals for the ratios of the means (test/reference) by exponentiation.
  • the products were considered bioequivalent if the 90% confidence intervals about the ratios of means for AUC and C max were contained within the limits 0.80 to 1.25.
  • the sampling schedule for ribavirin proved to be suitable for estimation of T max in this bioavailability study.
  • the first post-dose sample was not the maximum observed concentration after 94 of the 96 doses.
  • Two post-dose samples were obtained before the average time of the maximum concentration.
  • Geometric Mean (14515) (15003) (15337) Ln AUC 0-Inf 19.9716 ⁇ 0.02232 10.0689 ⁇ 0.02286 10.0594 ⁇ 0.02324 0.91+ 0.92+ 1.01 p ⁇ 0.05 Geometric Mean (21410) (23597) (23374) Ln C max 6.8316 ⁇ 0.03122 6.8451 ⁇ 0.03125 6.8737 ⁇ 0.03119 0.99 0.96 0.97 N.S.
  • Geometric Mean (926.7) (939.2) (966.5) AUC 0-T (ng ⁇ h/ml) 15108 ⁇ 414.3 15566 ⁇ 414.7 16051 t ⁇ 413.9 0.97 0.94 0.97 N.S.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This is a Continuation Application of U.S. Ser. No. 11/201,311 filed, Aug. 11, 2005, which claims priority to U.S. Provisional Application No. 60/619,013, filed Oct. 18, 2004. The disclosure of the prior applications is hereby incorporated herein in its entirety by reference.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The invention is generally directed to large dosage formulations of ribavirin.
  • 2. Background of the Invention
  • Ribavirin (1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carbamide) is a broad-spectrum antiviral nucleoside analog. It is available as a capsule and tablet in both the brand and generic form in 200 mg strength. The Food and Drug Administration has approved ribavirin in combination with interferon alfa-2a or interferon alfa-2b for the treatment of hepatitis-C. Over 170 million people worldwide are chronically infected with the hepatitis-C virus (HCV). Ribavirin is available as a 200 mg tablet by Roche Laboratories under the brand COPEGUS™ and as a 200 mg capsule by Schering-Plough under the brand REBETOL™.
  • The most common doses prescribed for patients are 800 mg, 1000 mg, and 1200 mg per day in divided doses for both the capsule and tablet dosage forms. These dosing regimens have the patient taking up to 6 capsules or tablets per day. Ribavirin is not often given by itself; it is generally a component of a multi-drug regimen (“drug cocktail”). Therefore patients taking ribavirin have to take a large number of drugs, not in the least of which is 4 to 6 capsules or tablets of ribavirin. Not surprisingly, lack of patient compliance is a significant issue.
  • HCV has about a 50 percent cure rate depending upon a patient's genotype. Everything must be done to ensure patient compliance to the therapy that lasts 6 to 12 months. If dosing is more convenient for the patient, then it follows that the patient will more likely comply with the dosing regimen for the duration of therapy, which has been proven to improve patient outcomes.
  • Therefore, there exists a long-felt need to make the dosing of ribavirin more convenient for the patient and increase patient compliance.
  • From a convenience standpoint, one logical approach to the formulator would be to formulate a modified or sustained release form of ribavirin, which would result in fewer capsules or tablets taken daily. However, in the case of ribavirin, such an approach would not be successful. The pharmacokinetics of ribavirin are controlled by the rate of elimination, not absorption. Therefore, modifying the rate of release or absorption of ribavirin would not likely affect the efficacy of ribavirin. In other words, sustained release formulations of ribavirin are likely not a solution in this instance.
  • The present inventors have concluded that in the case of ribavirin, the optimal dosage regimen is two times a day. The inventors then strove to formulate dosage forms with a twice-a-day dosing regimen which would increase patient compliance while maintaining bioactivity similar to lower (e.g., 200 mg) dose formulations.
    • SUMMARY OF THE INVENTION
  • One aspect of the present invention is directed to an oral dosage form of ribavirin, preferably a capsule, tablet or caplet, in 400 mg to 600 mg dosage strengths.
  • Another aspect of the present invention is directed to dosage forms of ribavirin that increase patient compliance.
  • Another aspect of the invention is directed to dosage forms of ribavirin that satisfy a long-felt need in the market for ribavirin dosage forms.
  • Another aspect of the invention is directed to dosage forms of ribavirin comprising high amounts of ribavirin, relative to commercially available formulations, which have similar bioactivities to the commercially available formulations.
  • A further aspect of the invention is directed to a dosage form comprising 400 mg of ribavirin.
  • A further aspect of the invention is directed to a dosage form comprising 600 mg of ribavirin.
  • Another aspect of the invention is directed to dosage forms of ribavirin in unit dose packaging, such as blister packaging.
  • Other aspects, features, and advantages of the invention will become apparent from the following detailed description and figure.
    • BRIEF DESCRIPTION OF THE FIGURE
  • FIG. 1 shows mean in vivo ribavirin plasma levels of three formulations in a bioavailability study of 36 subjects. COPEGUS™ 3×200 mg means that the brand name ribavirin product was given in a dosage of three 200 mg tablets. RIBASPHERE™ 3×200 mg means that the generic ribavirin product was given in a dosage of three 200 mg tablets. RIBASPHERE™ 1×600 mg means that a ribavirin product according to the invention was given at a dosage of one 600 mg tablet.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • In accordance with the present invention, the term “dosage form” includes capsules and tablets, and the term “tablet” includes both tablets and caplets. The dosage form of the invention is preferably a tablet, and more preferably a caplet.
  • The present application describes the development of dosage forms of ribavirin in 400 mg to 600 mg dosage strengths. In order to test bioequivalency, subjects were dosed with 600 mg tablets. A corresponding number of COPEGUS™ and generic 200 mg tablets were used as a comparison. FIG. 1 shows that the in vivo dissolution profile of a 600 mg tablet according to the present invention is similar to the dissolution profile of three 200 mg COPEGUS™ tablets. In other words, the higher strength tablets according to the present invention are bioequivalent to the brand name product. Further, the preferred caplet shape makes it easier for the patient to swallow and the tablets are acceptable as not being too large in size.
  • The patient now only has to take one tablet twice a day instead of 2 or 3 tablets twice a day. This new, more convenient dose keeps patients more compliant to their drug regimen, which improves outcomes. To this point, no drug manufacturer has manufactured a large dosage form of ribavirin. There is a clear and long-felt need in the industry for such a product.
  • The dosage forms of the present invention can be made of the same general ingredients (e.g., binders, fillers, disintegrants, lubricants and the like) and in the same manner as commercially available ribavirin tablets. In one embodiment of the present invention, a tablet comprises one or more of the following inactive ingredients: microcrystalline cellulose; lactose; crosscarmellose sodium; Povidone; and magnesium stearate. In another embodiment of the present invention, the tablet is coated and the coating preferably comprises: Opandry II Blue (which in turn comprises polyvinyl alcohol-part hydrolyzed, titanium dioxide, macrogel/PEG 3350, talc, and FD&C blue #2/indigo carmine aluminum lake); and carnauba wax.
  • One example of the formulation of a 400 mg ribavirin tablet in accordance with the present invention is shown in Table I:
  • TABLE I
    Component Weight/tablet (mg) Ingredient
    Active 400.0 Ribavirin
    Binder/disintegrant 84.4 Microcrystalline cellulose
    Filler 30.0 Lactose monohydrate
    Disintegrant 25.4 Crosscarmellose sodium
    Binder 6.0 Povidone
    Lubricant 4.2 Magnesium stearate
    Water (removed during Purified water
    drying)
  • One example of the formulation of a 600 mg ribavirin tablet in accordance with the present invention is shown in Table II:
  • TABLE II
    Component Weight/tablet (mg) Ingredient
    Active 600.0 Ribavirin
    Binder/disintegrant 126.6 Microcrystalline cellulose
    Filler 45.0 Lactose monohydrate
    Disintegrant 38.1 Crosscarmellose sodium
    Binder 9.0 Povidone
    Lubricant 6.3 Magnesium stearate
    Water (removed during Purified water
    drying)
  • One embodiment of a 400 mg tablet according to the present invention has hardness of from about 10.27 kp to about 12.88 kp, preferably 11.18 kp. Another embodiment of a 400 mg tablet according to the present invention has a tablet weight of from about 0.5470 g to about 0.5535 g, preferably 0.5494 g. Another embodiment of a 400 mg tablet according to the present invention has a tablet thickness of from about 4.86 mm to about 4.91 mm, preferably 4.89 mm. Another embodiment of a 400 mg tablet according to the present invention has a tablet friability of from about 0.23% to about 0.26%, preferably 0.25%. Another embodiment of a 400 mg tablet according to the present invention has a compression force of from about 13.5 kN to about 16.6 kN, preferably 14.9 kN.
  • One embodiment of a 600 mg tablet according to the present invention has hardness of from about 10.64 kp to about 12.58 kp, preferably 11.60 kp. Another embodiment of a 600 mg tablet according to the present invention has a tablet weight of from about 0.8174 g to about 0.8357 g, preferably 0.8272 g. Another embodiment of a 600 mg tablet according to the present invention has a tablet thickness of from about 6.38 mm to about 6.41 mm, preferably 6.39 mm. Another embodiment of a 600 mg tablet according to the present invention has a tablet friability of from about 0.23% to about 0.33%, preferably 0.29%. Another embodiment of a 600 mg tablet according to the present invention has a compression force of from about 12.2 kN to about 14.2 kN, preferably 13.1 kN.
  • Compression and film coating of the tablets according to the present invention may be accomplished by standard industry means. For example, tablets may be compressed using a 16-station Manesty Beta press using capsule shaped tooling. The tablets may be film coated using a 24-inch Accela Cota pan equipped with 2 spray guns with a target air flow of about 300 cfm and an exhaust temperature of between about 50° C. to 55° C. The pan speed and the target spray rate can be adjusted to suit the particular tablet being coated. As indicated previously, in one embodiment, Opandry II Blue coating is used. Any suitable coating can be used in accordance with the present invention.
  • The tablets according to the present invention may be of any color, preferably blue, more preferably light-blue, medium blue, or dark blue. The tablets can also be of any shape, preferably flat and oval-shaped. The tablets may be dispensed in any form including blister packs and HDPE bottles, which may or may not include child-resistant closures with induction seals. Any number of tablets may be included in a unit dose package, such as a blister pack, including 2, 4, 6, 8, 10, 12, 16, 20, 24, 48 or 56.
    • Example 1 A Comparative Bioavailability Study of Ribavirin Tablets Under Fasting Conditions
  • Ribavirin plasma levels under fasting conditions, produced after administration of (a) three Ribasphere® 200 mg tablets and (b) one Ribasphere® 600 mg tablet were compared with those produced after administration of three Copegus® 200 mg tablets.
  • The 200 mg and 600 mg Ribasphere® tablets are manufactured by Three Rivers Pharmaceuticals, LLC; ribavirin tablets. The Copegus® 200 mg tablets were manufactured by Roche®.
  • The study was administered and coordinated by Bioanalytical Systems, Inc. (BASi), Clinical Research Unit (CRU), Baltimore, Md. The clinical portion of the study was conducted by Gateway Medical Research, Inc. The laboratory analysis of plasma samples and statistical analysis of the concentration-time data was conducted at BASi CRU. Forty-one healthy female subjects were enrolled in this three-treatment crossover study. Blood samples from all subjects who completed the study were analyzed. The subjects received a single oral dose of ribavirin 600 mg on three occasions separated by a washout period of three weeks. Blood samples were obtained at 15 time points from predose (0-hour) until 72 hours post-dose. The plasma samples were analyzed by a specific validated LC/MS/MS method to determine ribavirin concentrations.
  • The ribavirin concentrations were used to calculate the area under the concentration-time curve to the last non-zero time point (AUC0-T), elimination rate constant (Kel), half-life (T1/2) and AUC 0-Infinity (AUC0-Inf). The actual times of sample collections were used in the calculations. The maximum drug concentration (Cmax) and the time to maximum drug concentration (Tmax) were also reported. The arithmetic mean and standard deviation were calculated for each parameter and for the ribavirin concentrations at each time point. The geometric means were calculated for AUC0-T, AUC0-Inf and Cmax. All parameters were analyzed by an analysis of variance (ANOVA) using the general linear model (GLM). The ANOVA included effects for sequence of drug treatment, subject nested within sequence, period and drug treatment in the statistical model. The F-test was employed to determine the statistical significance of each effect in the model. The sequence effect was tested using the subject (sequence) mean square as the error term (α=0.10), while the other effects were tested against the residual error (α=0.05). The power of the study to detect a 20% difference in parameter means as statistically significant under a 2-tailed test at the 5% level of the t-distribution was calculated for each pharmacokinetic metric.
  • The test and reference means (and geometric means), and the ratios of means, test/reference, were reported using the least squares means from the ANOVA. An assessment of bioequivalence was conducted for the test versus reference product comparison of AUC and Cmax after log transformation using 90% confidence intervals for the differences in treatment means. These were transformed into 90% confidence intervals for the ratios of the means (test/reference) by exponentiation. The products were considered bioequivalent if the 90% confidence intervals about the ratios of means for AUC and Cmax were contained within the limits 0.80 to 1.25.
  • Of the 41 subjects enrolled into the study, 36 subjects completed all study periods. The plasma samples were analyzed for all completed subjects. Several of the subjects experienced at least one adverse event. Ribavirin was measured in the predose sample of period I for one subject, in the predose sample of period II for nine subjects, and in the predose sample of period III for 21 subjects. The predose concentration detected was less than 5% of the individual Cmax value for all but four subjects.
  • The sampling schedule for ribavirin proved to be suitable for estimation of Tmax in this bioavailability study. The first post-dose sample was not the maximum observed concentration after 94 of the 96 doses. Two post-dose samples were obtained before the average time of the maximum concentration.
  • The sampling schedule was truncated at 72 hours post-dose for this long half-life drug, eighty percent of AUC0-Inf was not typically measured by AUC0-T. Therefore, in the results that follow, emphasis should be placed on AUC0-T, since AUC0-Inf was not generally well estimated.
  • There were no statistically significant (α=0.05) differences between the formulations for AUC0-T or Cmax, while there was a statistically significant formulation difference observed for AUC0-Inf. There were no statistically significant sequence effects (α=0.10) for any AUC or Cmax parameter, and there was no statistically significant period effects (α=0.05) for Cmax.
  • The results show that three ribavirin Ribasphere® 200 mg tablets is bioequivalent to three Copegus® 200 mg tablets when both were administered under fasting conditions. Similarly, the ribavirin Ribasphere® 600 mg is bioequivalent to three ribavirin Copegus® 200 mg tablets when administered under fasting conditions. For AUC0-T, AUC0-Inf and Cmax, the 90% confidence intervals were within the 0.80 to 1.25 bioequivalence limits for both comparisons.
  • TABLE III
    Ribavirin Ratio of Means 90% Confidence
    (n-32) (test/reference) Interval
    Ribasphere ® 3 × 200 mg vs. Copegus ® 3 × 200 mg
    AUC0-T 0.95 0.89; 1.00
    AUC0-Inf 0.92 0.87; 0.97
    Cmax 0.96 0.89; 1.03
    Ribasphere ® 1 × 600 mg vs. Copegus ® 3 × 200 mg
    AUC0-T 0.98 0.92; 1.04
    AUC0-Inf 1.01 0.96; 1.07
    Cmax 0.97 0.90; 1.05

    Based on least squares after logarithmic transformation of the data
  • TABLE IV
    RIBAVIRIN PLASMA CONCENTRATIONS (ng/ml)
    Test1: Ribasphere Test 2: Ribasphere Ref: Copegus
    Time 3 × 200 mg 1 × 600 mg 3 × 200 mg Ratio Ratio Ratio
    (Hours) N Mean ± Std Dev N Mean ± Std Dev N Mean ± Std Dev Test 1/Test 2 Test/Ref Test 2/Ref Significance
    0 32 9.319 ± 15.54 32 7.472 ± 13.36 32 8.713 ± 16.63 1.25 1.07 0.86
    0.5 32 435.0 ± 231.6 32 425.0 ± 255.1 32 348.5 ± 198.7 1.02 1.25 1.22 N.S.
    1 32 811.5 ± 312.7 32 806.9 ± 267.8 32 825.0 ± 328.2 1.01 0.98 0.98 N.S.
    1.5 32 859.2 ± 274.8 32 889.3 ± 317.9 32 965.6 ± 401.5 0.97 0.89 0.92 N.S.
    2 32 794.5 ± 302.5 32 817.0 ± 272.7 32 907.2 ± 390.6 0.97 0.88 0.90 N.S.
    3 32 648.3 ± 274.8 32 642.5 ± 221.2 32 706.0 ± 321.4 1.01 0.92 0.91 N.S.
    4 32 528.8 ± 186.5 32 533.0 ± 169.7 32 552.7 ± 223.4 0.99 0.96 0.96 N.S.
    6 32 419.5 ± 141.4 32 425.3 ± 151.1 32 422.1 ± 160.3 0.99 0.99 1.01 N.S.
    8 32 320.1 ± 89.66 32 340.8 ± 117.8 32 330.9 ± 105.1 0.94 0.97 1.03 N.S.
    12 32 246.5 ± 75.29 32 251.2 ± 81.48 32 260.2 ± 92.76 0.98 0.95 0.97 N.S.
    16 32 230.4 ± 77.53 32 234.2 ± 68.48 32 240.6 ± 78.96 0.98 0.9′6 0.97 N.S.
    24 32 211.2 ± 61.13 32 212.4 ± 70.36 32 214.9 ± 70.82 0.99 0.98 0.99 N.S.
    36 31 158.6 ± 55.79 32 163.1 ± 55.60 30 171.4 ± 54.10 0.97 0.92 0.95 N.S.
    48 31 136.0 ± 44.73 32 146.6 ± 42.12 32 152.7 ± 53.24 0.93 0.89+ 0.96 p < 0.05
    72 32 106.0 ± 43.65 32 110.5 ± 35.09 32 111.4 ± 37.46 0.96 0.95 0.99 N.S.
  • TABLE V
    PHARMACOKINETIC PARAMETERS FOR PLASMA RIBAVIRIN
    Test1: Ribasphere Test 2: Ribasphere Ref: Copegus
    3 × 200 mg 1 × 600 mg 3 × 200 mg Ratio Ratio Ratio
    Parameter N Mean ± Std Dev N Mean ± Std Dev N Mean ± Std Dev Test 1/Test 2 Test 1/Ref Test 2/Ref
    Ln AUC
    0-T 32 9.5776 ± 0.2769 32 9.6097 ± 0.2683 32 9.6302 ± 0.3008 0.97 0.95 0.98
    Geometric Mean 14438 14909 15218
    Ln AUC 0-Inf 32 9.9712 ± 0.3326 31 10.0599 ± 0.3161  30 10.0579 ± 0.3264  0.92 0.92 1.00
    Geometric Mean 21401 23387 23339
    Ln C max 32 6.8292 ± 0.3181 32 6.8435 ± 0.2937 32 6.8703 ± 0.3793 0.99 0.96 0.97
    Geometric Mean    924.4    937.8    963.2
    AUC0-T (ng · h/ml) 32 15002 ± 4413  32 15447 ± 4288  32 15902 ± 4864  0.97 0.94 0.97
    AUC0-Inf (ng · h/ml) 32 22645 ± 8290  31 24570 ± 8091  30 24576 ± 8255  0.92 0.92 1.00
    Cmax (ng/ml) 32 971.1 ± 314.4 32 979.9 ± 315.9 32  1033 ± 402.6 0.99 0.94 0.95
    Tmax (h) 32  1.501 ± 0.5680 32  1.455 ± 0.5605 32  1.517 ± 0.5301 1.03 0.99 0.96
    Kel (1/h) 32  0.01531 ± 0.003645 31  0.01407 ± 0.003963 30  0.01484 ± 0.003230 1.09 1.03 0.95
    T1/2 (h) 32 47.69 ± 10.71 31 53.61 ± 16.65 30 49.22 ± 12.41 0.89 0.97 1.09
  • TABLE VI
    PHARMACOKINETIC PARAMETERS FOR PLASMA RIBAVIRIN
    Test 1 Ribasphere Test 2 Ribasphere Reference Copegus Ratio Ratio Ratio
    Parameter 3 × 200 mg 1 × 600 mg 3 × 200 mg Test I/Test 2 Test 1/Ref Test 2/Ref Significance
    Ln AUC0-T  9.5829 ± 0.02500  9.6160 ± 0.02502  9.6380 ± 0.02497 0.97 0.95 0.98 N.S.
    Geometric Mean (14515) (15003) (15337)
    Ln AUC0-Inf 19.9716 ± 0.02232 10.0689 ± 0.02286 10.0594 ± 0.02324 0.91+ 0.92+ 1.01 p < 0.05
    Geometric Mean (21410) (23597) (23374)
    Ln Cmax  6.8316 ± 0.03122  6.8451 ± 0.03125  6.8737 ± 0.03119 0.99 0.96 0.97 N.S.
    Geometric Mean    (926.7)    (939.2)    (966.5)
    AUC0-T (ng · h/ml) 15108 ± 414.3  15566 ± 414.7  16051 t ± 413.9 0.97 0.94 0.97 N.S.
    AUC0-Inf (ng · h/ml) 22722 ± 625.5  24820 ± 640.9  24687 ± 651.4  0.92 0.92 1.01 p < 0.05
    Cmax (ng/ml) 974.6 ± 34.31 983.3 ± 34.34  1038 ± 34.28 0.99 0.94 0.95 N.S.
    Tmax (h)  1.487 ± 0.09425  1.457 ± 0.09435  1.511 ± 0.09416 1.02 0.98 0.96 N.S.
    Kel (1/h)  0.01542 ± 0.000410  0.01393 ± 0.000420  0.01474 ± 0.000427 1.11+ 1.05 0.95 p < 0.05
    T1/2 (h) 47.29 ± 1.639 54.27 ± 1.679 49.74 ± 1.707 0.87+ 0.95 1.09 p < 0.05
  • TABLE VII
    PHARMACOKINETIC PARAMETERS FOR PLASMA RIBAVIRIN
    Contrast Measured Ratio Study Intrasubject 90% Confidence
    of Means Parameter (Test/Ref) Power C.V. (%) Interval
    Ribasphere 3 × 200 mg Ln AUC0-T 0.97 >0.99 14.1 [0.91; 1.03]
    vs. Ribasphere Ln AUC0-Inf 0.91 >0.99 12.6 [0.86; 0.96]
    1 × 600 mg Ln Cmax 0.99 >0.99 17.7 [0.92; 1.06]
    AUC0-T (ng · h/ml) 0.97 >0.99 15.1 [0.91; 1.03]
    AUC0-Inf (ng · h/ml) 0.92 >0.99 14.7 [0.86; 0.98]
    Cmax (ng/ml) 0.99 0.98 19.4 [0.91; 1.07]
    Ribasphere 3 × 200 mg Ln AUC0-T 0.95 >0.99 14.1 [0.89; 1.00]
    vs. Copegus 3 × 200 mg Ln AUC0-Inf 0.92 >0.99 12.6 [0.87; 0.97]
    Ln Cmax 0.96 >0.99 17.7 [0.89; 1.03]
    AUC0-T (ng · h/ml) 0.94 >0.99 15.1 [0.88; 1.00]
    AUC0-Inf (ng · h/ml) 0.92 >0.99 14.7 [0.86; 0.98]
    Cmax (ng/ml) 0.94 0.99 19.4 [0.86; 1.02]
    Ribasphere 1 × 600 mg Ln AUC0-T 0.98 >0.99 14.1 [0.92; 1.04]
    vs. Copegus 3 × 200 mg Ln AUC0-Inf 1.01 >0.99 12.6 [0.96; 1.07]
    Ln Cmax 0.97 >0.99 17.7 [0.90; 1.05]
    AUC0-T (ng · h/ml) 0.97 >0.99 15.1 [0.91; 1.03]
    AUC0-Inf (ng · b/ml) 1.01 >0.99 14.7 [0.94; 1.07]
    Cmax (ng/ml) 0.95 0.99 19.4 [0.87; 1.02]
  • It is to be understood that while the invention has been described above using specific embodiments, the description and examples are intended to illustrate the structural and functional principles of the present invention and are not intended to limit the scope of the invention. On the contrary, the present invention is intended to encompass all modifications, alterations, and substitutions.

Claims (15)

1. A method for increasing patient compliance of a therapy comprising ribavirin, the method comprising administering a single pharmaceutical dosage form comprising 400 mg to 600 mg of ribavirin.
2. The method of claim 1, wherein the dosage form comprises 400 mg of ribavirin and further comprises at least one excipient selected from the group consisting of microcrystalline cellulose, lactose monohydrate, crosscarmellose sodium, povidone and magnesium stearate.
3. The method of claim 1, wherein the dosage form comprises 600 mg of ribavirin and further comprises at least one excipient selected from the group consisting of microcrystalline cellulose, lactose monohydrate, crosscarmellose sodium, povidone and magnesium stearate.
4. A method for increasing patient compliance of a therapy comprising ribavirin, the method comprising administering, twice a day to a subject, exactly one dosage form comprising 400 mg to 600 mg of ribavirin.
5. The method of claim 4, wherein the dosage form comprises 400 mg of ribavirin and further comprises at least one excipient selected from the group consisting of microcrystalline cellulose, lactose monohydrate, crosscarmellose sodium, povidone and magnesium stearate.
6. The method of claim 4, wherein the dosage form is a 400 mg tablet which has at least one of the following characteristics:
a tablet hardness of from about 10.27 kp to about 12.88 kp;
a tablet weight of from about 0.5470 g to about 0.5535 g;
a tablet thickness of from about 4.86 mm to about 4.91 mm; and
a tablet friability of from about 0.23% to about 0.26%.
7. The method of claim 4, wherein the dosage form comprises 600 mg of ribavirin and further comprises at least one excipient selected from the group consisting of microcrystalline cellulose, lactose monohydrate, crosscarmellose sodium, povidone and magnesium stearate.
8. The method of claim 4, wherein the dosage form is a 600 mg tablet which has at least one of the following characteristics:
a tablet hardness of from about 10.64 kp to about 12.58 kp;
a tablet weight of from about 0.8174 g to about 0.8357 g;
a tablet thickness of from about 6.38 mm to about 6.41 mm; and
a tablet friability of from about 0.23% to about 0.33%.
9. The method according to claim 4, wherein the dosage form is a tablet which is dispensed in HDPE bottles.
10. The method according to claim 4, wherein the dosage form is a tablet which is dispensed in a unit dose package.
11. The method according to claim 10, wherein the unit dose package is a blister pack containing 2, 4, 6, 8, 10, 12, 16, 20, 24, 48 or 56 tablets.
12. A daily dosage regimen of ribavirin treatment comprising administering to a patient in need thereof exactly one dosage form of ribavirin and 8 hours to 16 hours later administering another one dosage form of ribavirin.
13. The daily dosage regimen of claim 12, wherein the dosage form comprises 400 mg to 600 mg of ribavirin.
14. The daily dosage regimen of claim 13, wherein the dosage form is a tablet which comprises 400 mg of ribavirin.
15. The daily dosage regimen of claim 13, wherein the dosage form is a tablet which comprises 600 mg of ribavirin.
US12/761,869 2004-10-18 2010-04-16 Large dose ribavirin formulations Abandoned US20100203127A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/761,869 US20100203127A1 (en) 2004-10-18 2010-04-16 Large dose ribavirin formulations
US13/441,560 US20120207828A1 (en) 2004-10-18 2012-04-06 Large dose ribavirin formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61901304P 2004-10-18 2004-10-18
US11/201,311 US7723310B2 (en) 2004-10-18 2005-08-11 Large dose ribavirin formulations
US12/761,869 US20100203127A1 (en) 2004-10-18 2010-04-16 Large dose ribavirin formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/201,311 Continuation US7723310B2 (en) 2004-10-18 2005-08-11 Large dose ribavirin formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/441,560 Continuation US20120207828A1 (en) 2004-10-18 2012-04-06 Large dose ribavirin formulations

Publications (1)

Publication Number Publication Date
US20100203127A1 true US20100203127A1 (en) 2010-08-12

Family

ID=36181049

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/201,311 Active 2028-02-08 US7723310B2 (en) 2004-10-18 2005-08-11 Large dose ribavirin formulations
US12/180,139 Abandoned US20090012015A1 (en) 2004-10-18 2008-09-19 Large dose ribavrin formulatons
US12/761,869 Abandoned US20100203127A1 (en) 2004-10-18 2010-04-16 Large dose ribavirin formulations
US13/441,560 Abandoned US20120207828A1 (en) 2004-10-18 2012-04-06 Large dose ribavirin formulations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/201,311 Active 2028-02-08 US7723310B2 (en) 2004-10-18 2005-08-11 Large dose ribavirin formulations
US12/180,139 Abandoned US20090012015A1 (en) 2004-10-18 2008-09-19 Large dose ribavrin formulatons

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/441,560 Abandoned US20120207828A1 (en) 2004-10-18 2012-04-06 Large dose ribavirin formulations

Country Status (1)

Country Link
US (4) US7723310B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090012015A1 (en) * 2004-10-18 2009-01-08 Three Rivers Pharmaceuticals, Llc Large dose ribavrin formulatons

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
US20070161583A1 (en) * 2004-10-18 2007-07-12 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA201490837A1 (en) 2011-10-21 2014-11-28 Эббви Инк. METHODS OF TREATING HCV, INCLUDING, AT THE LITERATURE, TWO ANTI-VIRAL AGENTS OF DIRECT ACTION, RIBAVIRIN, BUT NOT INTERFERON
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9119971B2 (en) 2012-07-26 2015-09-01 Zoll Medical Corporation Automated external defibrillator configuration
WO2016160851A1 (en) 2015-03-30 2016-10-06 Zoll Medical Corporation Customer-or patient-based selective data encryption in medical device management
CN107615396B (en) 2015-03-30 2022-06-28 卓尔医疗公司 Clinical data transfer and data sharing in equipment management
JP2018515832A (en) 2015-03-30 2018-06-14 ゾール メディカル コーポレイションＺＯＬＬ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ Medical device management
US10665341B2 (en) 2015-03-30 2020-05-26 Zoll Medical Corporation Customer—or patient-based selective data encryption in medical device management
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
PL3720424T3 (en) 2017-12-08 2022-12-27 F. Hoffmann-La Roche Ag Pharmaceutical formulation

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971951A (en) * 1987-06-15 1990-11-20 Garcia Y Bellon Donato P Insulin potentiation therapy
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5549204A (en) * 1992-02-26 1996-08-27 Toren Consulting Pty. Ltd. Blister packs
US20010048988A1 (en) * 1999-09-28 2001-12-06 Glenn J. Forte Polyolefin bottles and method for making same
US6337090B1 (en) * 1997-12-22 2002-01-08 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US20030104050A1 (en) * 2001-11-02 2003-06-05 Matharu Amol Singh Process for preparing quick dissolving, high loading ribavirin compositions
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
US20050019406A1 (en) * 2002-09-19 2005-01-27 Three Rivers Pharmaceuticals, Llc Composition containing ribavirin and use thereof
US20050281872A1 (en) * 2004-06-16 2005-12-22 Peter Summerville Enhanced compliance antiviral medicaments and methods of manufacture and use
US20060083785A1 (en) * 2004-10-18 2006-04-20 Kerrish Donald J Large dose ribavirin formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
AU742943B2 (en) 1997-12-22 2002-01-17 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU2156900A (en) 1998-12-18 2000-07-12 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971951A (en) * 1987-06-15 1990-11-20 Garcia Y Bellon Donato P Insulin potentiation therapy
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5549204A (en) * 1992-02-26 1996-08-27 Toren Consulting Pty. Ltd. Blister packs
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6337090B1 (en) * 1997-12-22 2002-01-08 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US20010048988A1 (en) * 1999-09-28 2001-12-06 Glenn J. Forte Polyolefin bottles and method for making same
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
US20030104050A1 (en) * 2001-11-02 2003-06-05 Matharu Amol Singh Process for preparing quick dissolving, high loading ribavirin compositions
US20050019406A1 (en) * 2002-09-19 2005-01-27 Three Rivers Pharmaceuticals, Llc Composition containing ribavirin and use thereof
US20050281872A1 (en) * 2004-06-16 2005-12-22 Peter Summerville Enhanced compliance antiviral medicaments and methods of manufacture and use
US20060083785A1 (en) * 2004-10-18 2006-04-20 Kerrish Donald J Large dose ribavirin formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090012015A1 (en) * 2004-10-18 2009-01-08 Three Rivers Pharmaceuticals, Llc Large dose ribavrin formulatons

Also Published As

Publication number Publication date
US7723310B2 (en) 2010-05-25
US20120207828A1 (en) 2012-08-16
US20060083785A1 (en) 2006-04-20
US20090012015A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
US20100203127A1 (en) Large dose ribavirin formulations
CA2754853C (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EP2190418B1 (en) Immediate release and sustained release ibuprofen dosing regimen
CN100358518C (en) Pharmaceutical composition containing terbinafine and application thereof
EP3395331A1 (en) Pharmaceutical tablet composition comprising eltrombopag olamine
EP3421033B1 (en) Hiv treatment formulation of atazanavir and cobicistat
US20070161583A1 (en) Large dose ribavirin formulations
EP4376807A1 (en) A pharmaceutical composition comprising combination of sglt2 inhibitor and dpp-iv inhibitor
WO2018028841A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
EP3334419A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
Tarapon et al. Development of extended-release formulation based on the quality by design approach
US20080167325A1 (en) Valacyclovir compositions
EP3335701A1 (en) Pharmaceutical composition comprising omarigliptin
US20130017254A1 (en) Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
Kambayashi et al. Biowaiver monograph for immediate-release solid oral dosage forms: Raltegravir potassium
HK40002830B (en) Hiv treatment formulation of atazanavir and cobicistat
HK40002830A (en) Hiv treatment formulation of atazanavir and cobicistat
HK40081251A (en) Pharmaceutical formulations
Jantratid et al. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine This paper reflects the scientific opinion of the authors and not the policies of regulating agencies.
MIDHA et al. E. JANTRATID, S. PRAKONGPAN, JB DRESSMAN, 2 GL AMIDON, 3 HE JUNGINGER, 4

Legal Events

Date Code Title Description
AS Assignment

Owner name: THREE RIVERS PHARMACEUTICALS, LLC, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KERRISH, DONALD JOSEPH;DHANANTWARI, RAVINDRA;REEL/FRAME:024256/0441

Effective date: 20050809

AS Assignment

Owner name: THREE RIVERS PHARMACEUTICALS, LLC, PENNSYLVANIA

Free format text: CHANGE OF ADDRESS;ASSIGNOR:THREE RIVERS PHARMACEUTICALS, LLC;REEL/FRAME:024414/0922

Effective date: 20100512

AS Assignment

Owner name: SUNTRUST BANK, AS ADMINISTRATIVE AGENT, GEORGIA

Free format text: SECURITY AGREEMENT;ASSIGNORS:THREE RIVERS PHARAMCEUTICALS, LLC;THREE RIVERS PHARMACEUTICALS, LLC;REEL/FRAME:024678/0603

Effective date: 20100712

AS Assignment

Owner name: THREE RIVERS PHARMACEUTICALS, LLC, NEW YORK

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SUNTRUST BANK, AS ADMINISTRATIVE AGENT;REEL/FRAME:025332/0385

Effective date: 20101022

Owner name: CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTR

Free format text: SECURITY AGREEMENT;ASSIGNOR:THREE RIVERS PHARMACEUTICALS, LLC;REEL/FRAME:025321/0502

Effective date: 20101022

AS Assignment

Owner name: CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTR

Free format text: SECURITY AGREEMENT;ASSIGNOR:KADMON PHARMACEUTICALS, LLC;REEL/FRAME:027280/0954

Effective date: 20111031

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION